Advertisement
Canada markets open in 4 hours 43 minutes

  • S&P/TSX

    21,714.54
    -297.08 (-1.35%)
     

  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     

  • DOW

    37,815.92
    -570.17 (-1.49%)
     

  • CAD/USD

    0.7262
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    80.88
    -1.05 (-1.28%)
     

  • Bitcoin CAD

    78,227.57
    -7,420.27 (-8.66%)
     

  • CMC Crypto 200

    1,224.66
    -114.41 (-8.55%)
     

  • GOLD FUTURES

    2,296.00
    -6.90 (-0.30%)
     

  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     

  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     

  • NASDAQ futures

    17,471.00
    -100.25 (-0.57%)
     

  • VOLATILITY

    15.82
    +0.17 (+1.09%)
     

  • FTSE

    8,169.49
    +25.36 (+0.31%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6804
    +0.0002 (+0.03%)
     

VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting

Business Wire
·2 min read

NaturalVue® Multifocal 1 Day Contact Lenses Confirmed Safe & Effective for Myopia Management

NEW ORLEANS, October 12, 2023--(BUSINESS WIRE)--Visioneering Technologies, Inc. (ASX:VTI), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, presented interim data from the PROTECT Clinical Trial at the American Academy of Optometry's annual meeting. Interim 1-year data from the PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) clinical trial, conducted across four countries, demonstrated the safety and effectiveness of NaturalVue Multifocal ("NVMF") contact lenses in controlling myopia progression in pediatric patients.

Findings:

The preliminary 1-year findings affirmed NVMF’s effectiveness in slowing myopia progression. Over 12 months, the treatment effect yielded a 69% (0.41Diopter) reduction in refractive error compared to the control group. For axial length, the treatment effect measured 0.17 mm, a notable 59% reduction. This data aligns with prior real-world analyses, further validating NVMF’s efficacy.

ADVERTISEMENT

Note: Preliminary data; further review and analysis to be completed; additional insights to be shared in January 2024.

Dr. Ashley Tuan, VTI's Chief Medical Officer, expressed:

"The preliminary 1-year data confirms our belief in the safety and effectiveness of NaturalVue Multifocal for pediatric patients. NVMF not only ensures clear vision but also effectively manages myopia. The interim 1-year treatment effects are consistent with those of the only treatment approved by the U.S. Food and Drug Administration for myopia progression control. We eagerly anticipate sharing more insights from the study."

VTI's CEO, Dr. Juan Carlos Aragón, added:

"VTI's innovative and easily adaptable lens design plays a pivotal role in tackling pediatric myopia, one of the most pressing concerns in optometry today. We're thrilled to unveil the 1-year interim results of our PROTECT RCT, demonstrating the effectiveness of NaturalVue Multifocal in managing myopia in children."

To download the PROTECT Fact Sheet, click here. Visioneering Technologies Inc. focuses on groundbreaking vision care solutions, with its flagship product being the NaturalVue Multifocal 1-Day Contact Lens. For more information, visit www.vtivision.com or call +1 844-884-5367, ext. 104.

*Modified PP (Per Protocol) analysis including children between baseline ages 8 and <13 with refractive error between -0.75 and -4.00 D versus age-matched controls wearing spherical lenses. SD = standard deviation

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012143852/en/

Contacts

Layna L. Mendlinger
info@vtivision.com